These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 8028228

  • 1. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats.
    Matsui T, Nakamura Y, Ishikawa H, Matsuura A, Kobayashi F.
    Jpn J Pharmacol; 1994 Feb; 64(2):115-24. PubMed ID: 8028228
    [Abstract] [Full Text] [Related]

  • 2. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, Abe N, Fukushima K, Matsuura A.
    Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
    [Abstract] [Full Text] [Related]

  • 3. Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy in rats.
    Inukai S, Agata M, Sato M, Naitou A, Matsukawa H, Goto M.
    Jpn J Pharmacol; 1993 Mar; 61(3):221-7. PubMed ID: 8483299
    [Abstract] [Full Text] [Related]

  • 4. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat.
    Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, Ohkubo Y, Notsu Y, Yamaguchi I.
    Metabolism; 1991 Jan; 40(1):77-87. PubMed ID: 1898618
    [Abstract] [Full Text] [Related]

  • 5. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D, Mirrlees DJ, Harrison HE, Earl DC.
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [Abstract] [Full Text] [Related]

  • 6. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K.
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [Abstract] [Full Text] [Related]

  • 7. Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations.
    Horie S, Nagai H, Yuuki T, Narita Y, Tsuda Y, Nakajima T, Nakamura N.
    J Diabetes Complications; 1998 Feb; 12(3):163-9. PubMed ID: 9618072
    [Abstract] [Full Text] [Related]

  • 8. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y.
    Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
    [Abstract] [Full Text] [Related]

  • 9. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
    Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y, Terashima H, Morimura T, Tsuboshima M.
    Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
    [Abstract] [Full Text] [Related]

  • 10. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 11. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.
    Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiya H, Ienaga K, Sakakibara F, Koh N, Hotta N.
    Diabetes; 1999 Oct; 48(10):2090-5. PubMed ID: 10512378
    [Abstract] [Full Text] [Related]

  • 12. Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447: minor contribution of nitric oxide.
    Yoshida M, Sugiyama Y, Akaike N, Ashizawa N, Aotsuka T, Ohbayashi S, Matsuura A.
    Diabetes Res Clin Pract; 1998 May; 40(2):101-12. PubMed ID: 9681275
    [Abstract] [Full Text] [Related]

  • 13. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 May; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 14. Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats.
    Nishikawa M, Yoshida K, Okamoto M, Itoh Y, Kohsaka M.
    J Antibiot (Tokyo); 1991 Apr; 44(4):441-4. PubMed ID: 1903376
    [Abstract] [Full Text] [Related]

  • 15. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M.
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
    Hotta N, Kakuta H, Fukasawa H, Kimura M, Koh N, Iida M, Terashima H, Morimura T, Sakamoto N.
    Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.